The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System

Chronic primary pain (CPP) is a group of diseases with long-term pain and functional disorders but without structural or specific tissue pathologies. CPP is becoming a serious health problem in clinical practice due to the unknown cause of intractable pain and high cost of health care yet has not been satisfactorily addressed. During the past decades, a significant role for the descending pain modulation and alterations due to specific diseases of CPP has been emphasized. It has been widely established that central sensitization and alterations in neuroplasticity induced by the enhancement of descending pain facilitation and/or the impairment of descending pain inhibition can explain many chronic pain states including CPP. The descending serotonergic neurons in the raphe nuclei target receptors along the descending pain circuits and exert either pro- or antinociceptive effects in different pain conditions. In this review, we summarize the possible underlying descending pain regulation mechanisms in CPP and the role of serotonin, thus providing evidence for potential application of analgesic medications based on the serotonergic system in CPP patients.

[1]  M. Neumeister,et al.  Fibromyalgia. , 2020, Clinics in plastic surgery.

[2]  Imen Ayouni,et al.  Comorbidity between fibromyalgia and temporomandibular disorders: a systematic review. , 2019, Oral surgery, oral medicine, oral pathology and oral radiology.

[3]  Tao Yang,et al.  Rostral ventromedial medulla‐mediated descending facilitation following P2X7 receptor activation is involved in the development of chronic post‐operative pain , 2019, Journal of neurochemistry.

[4]  Xi Xiao,et al.  MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7. , 2019, Biochemical and biophysical research communications.

[5]  R. Ohrbach,et al.  Characteristics Associated With High-Impact Pain in People With Temporomandibular Disorder: A Cross-Sectional Study. , 2019, The journal of pain : official journal of the American Pain Society.

[6]  Yang Xue,et al.  Spinal 5-HT3 receptor contributes to somatic hyperalgesia induced by sub-chronic stress , 2019, Molecular pain.

[7]  F. Fregni,et al.  Potency of descending pain modulatory system is linked with peripheral sensory dysfunction in fibromyalgia , 2019, Medicine.

[8]  Blair H. Smith,et al.  The IASP classification of chronic pain for ICD-11: applicability in primary care , 2019, Pain.

[9]  S. Witt,et al.  Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome , 2018, NeuroImage: Clinical.

[10]  A. Artola,et al.  5-HT2A Receptor-Induced Morphological Reorganization of PKCγ-Expressing Interneurons Gates Inflammatory Mechanical Allodynia in Rat , 2018, The Journal of Neuroscience.

[11]  J. Grau,et al.  Ionic plasticity and pain: The loss of descending serotonergic fibers after spinal cord injury transforms how GABA affects pain , 2018, Experimental Neurology.

[12]  R. Khoury,et al.  The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update , 2018, Expert opinion on investigational drugs.

[13]  Jian Wang,et al.  Top-down descending facilitation of spinal sensory excitatory transmission from the anterior cingulate cortex , 2018, Nature Communications.

[14]  Aihui Li,et al.  Electroacupuncture alleviates chemotherapy‐induced pain through inhibiting phosphorylation of spinal CaMKII in rats , 2018, European journal of pain.

[15]  P. Martelletti,et al.  Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential , 2018, Journal of pain research.

[16]  N. Üçeyler,et al.  Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia , 2018, The Cochrane database of systematic reviews.

[17]  O. Gunduz,et al.  Contribution of spinal 5-HT5A receptors to the antinociceptive effects of systemically administered cannabinoid agonist WIN 55,212-2 and morphine. , 2018, Canadian journal of physiology and pharmacology.

[18]  Asensi Cabo-Meseguer,et al.  Fibromialgia: prevalencia, perfiles epidemiológicos y costes económicos , 2017 .

[19]  N. Waszkiewicz,et al.  Antidepressants for irritable bowel syndrome—A systematic review , 2017, Pharmacological reports : PR.

[20]  H. Obata Analgesic Mechanisms of Antidepressants for Neuropathic Pain , 2017, International journal of molecular sciences.

[21]  A. Eschalier,et al.  Disruption of 5-HT2A-PDZ protein interaction differently affects the analgesic efficacy of SSRI, SNRI and TCA in the treatment of traumatic neuropathic pain in rats , 2017, Neuropharmacology.

[22]  E. Lacivita,et al.  The brain-penetrant 5-HT7 receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain , 2017, Neurobiology of Disease.

[23]  O. Lyubashina,et al.  The 5-HT4 receptor-mediated inhibition of visceral nociceptive neurons in the rat caudal ventrolateral medulla , 2017, Neuroscience.

[24]  C. Bandala,et al.  Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System , 2017, Current neuropharmacology.

[25]  J. Rodríguez-Silverio,et al.  Spinal 5-HT_4 and 5-HT_6 receptors contribute to the maintenance of neuropathic pain in rats , 2017, Pharmacological reports : PR.

[26]  H. Choo,et al.  Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT6 receptor antagonists. , 2017, Bioorganic & medicinal chemistry letters.

[27]  F. Brocard,et al.  Activation of 5-HT2A Receptors Restores KCC2 Function and Reduces Neuropathic Pain after Spinal Cord Injury , 2017, Neuroscience.

[28]  E. Verdú,et al.  Neuroplasticity of Supraspinal Structures Associated with Pathological Pain , 2017, Anatomical record.

[29]  M. Low,et al.  Lorcaserin improves glycemic control via a melanocortin neurocircuit , 2017, Molecular metabolism.

[30]  Josephine M. Mancuso,et al.  Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults: A Systematic Review and Meta-Analysis , 2017, Journal of General Internal Medicine.

[31]  M. Zhuo,et al.  Characterization of serotonin-induced inhibition of excitatory synaptic transmission in the anterior cingulate cortex , 2017, Molecular Brain.

[32]  A. Pertovaara,et al.  The medullary dorsal reticular nucleus as a relay for descending pronociception induced by the mGluR5 in the rat infralimbic cortex , 2017, Neuroscience.

[33]  R. Chou,et al.  Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline , 2017, Annals of Internal Medicine.

[34]  A. Dickenson,et al.  An investigation into the inhibitory function of serotonin in diffuse noxious inhibitory controls in the neuropathic rat , 2017, European journal of pain.

[35]  A. Eschalier,et al.  Increasing spinal 5‐HT2A receptor responsiveness mediates anti‐allodynic effect and potentiates fluoxetine efficacy in neuropathic rats. Evidence for GABA release , 2017, Pharmacological research.

[36]  A. D. Nozdrachev,et al.  Antinociceptive effect of the agonist of 5-HT1A receptors buspirone in the model of abdominal pain in dogs , 2017, Doklady Biological Sciences.

[37]  V. Neugebauer,et al.  5-HT2C Receptor Knockdown in the Amygdala Inhibits Neuropathic-Pain-Related Plasticity and Behaviors , 2017, The Journal of Neuroscience.

[38]  A. Pertovaara,et al.  Descending antinociception induced by secondary somatosensory cortex stimulation in experimental neuropathy: role of the medullospinal serotonergic pathway. , 2017, Journal of neurophysiology.

[39]  N. Coimbra,et al.  5-Hydroxytryptamine2A/2C receptors of nucleus raphe magnus and gigantocellularis/paragigantocellularis pars α reticular nuclei modulate the unconditioned fear-induced antinociception evoked by electrical stimulation of deep layers of the superior colliculus and dorsal periaqueductal grey matter , 2017, Behavioural Brain Research.

[40]  R. Lewis‐Fernández,et al.  An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder , 2016, Journal of clinical psychopharmacology.

[41]  J. Fiedler,et al.  What Do We Really Know About 5-HT1A Receptor Signaling in Neuronal Cells? , 2016, Front. Cell. Neurosci..

[42]  A. U. Khan,et al.  The μ1-opioid receptor and 5-HT2A- and 5HT2C-serotonergic receptors of the locus coeruleus are critical in elaborating hypoalgesia induced by tonic and tonic–clonic seizures , 2016, Neuroscience.

[43]  R. Dong,et al.  The 5-HT2A receptor potassium-chloride cotransporter 2 signaling pathway in a rat incision pain model , 2016, Experimental and therapeutic medicine.

[44]  M. Sulaiman,et al.  Zerumbone alleviates chronic constriction injury-induced allodynia and hyperalgesia through serotonin 5-HT receptors. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  P. Svensson,et al.  Headaches and myofascial temporomandibular disorders: overlapping entities, separate managements? , 2016, Journal of oral rehabilitation.

[46]  V. Granados-Soto,et al.  Role of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine and valerenic acid in the rat formalin test. , 2016, European journal of pharmacology.

[47]  V. Granados-Soto,et al.  Role of spinal 5-HT_2 receptors subtypes in formalin-induced long-lasting hypersensitivity , 2016, Pharmacological reports : PR.

[48]  P. Siddall,et al.  Descending pain modulation in irritable bowel syndrome (IBS): a systematic review and meta-analysis , 2015, Systematic Reviews.

[49]  Wei-Hsin Sun,et al.  Serotonin Receptor 2B Mediates Mechanical Hyperalgesia by Regulating Transient Receptor Potential Vanilloid 1 , 2015, Journal of Molecular Neuroscience.

[50]  M. Ernberg,et al.  Repeated tender point injections of granisetron alleviate chronic myofascial pain - a randomized, controlled, double-blinded trial , 2015, The Journal of Headache and Pain.

[51]  V. Granados-Soto,et al.  Role of spinal 5-HT5A, and 5-HT1A/1B/1D, receptors in neuropathic pain induced by spinal nerve ligation in rats , 2015, Brain Research.

[52]  E. Calandre,et al.  Amitriptyline for the treatment of fibromyalgia: a comprehensive review , 2015, Expert review of neurotherapeutics.

[53]  T. Ness,et al.  Serotonin enhances urinary bladder nociceptive processing via a 5-HT3 receptor mechanism , 2015, Neuroscience Letters.

[54]  R. Nirogi,et al.  5-HT_6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids , 2015, Pharmacological reports : PR.

[55]  Lin Lin,et al.  Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis , 2015, PloS one.

[56]  G. Úrrutia,et al.  Selective serotonin reuptake inhibitors for fibromyalgia syndrome. , 2015, The Cochrane database of systematic reviews.

[57]  R. Sterzi,et al.  Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. , 2015, The Cochrane database of systematic reviews.

[58]  R. Miledi,et al.  Expression of hippocampal serotonin receptors 5-HT2C and 5-HT5A in a rat model of diet-induced obesity supplemented with tryptophan , 2015, International Journal of Developmental Neuroscience.

[59]  T. Schwartz,et al.  Downregulation of 5-HT7 Serotonin Receptors by the Atypical Antipsychotics Clozapine and Olanzapine. Role of Motifs in the C-Terminal Domain and Interaction with GASP-1. , 2015, ACS chemical neuroscience.

[60]  G. Dobos,et al.  Somatoform disorders and medically unexplained symptoms in primary care. , 2015, Deutsches Arzteblatt international.

[61]  A. Pertovaara,et al.  Bidirectional amygdaloid control of neuropathic hypersensitivity mediated by descending serotonergic pathways acting on spinal 5-HT3 and 5-HT1A receptors , 2015, Behavioural Brain Research.

[62]  Blair H. Smith,et al.  A classification of chronic pain for ICD-11 , 2015, Pain.

[63]  D. Lucini,et al.  Autonomic nervous system dysregulation in irritable bowel syndrome , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[64]  P. Rhee,et al.  The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D) , 2015, Therapeutic advances in gastroenterology.

[65]  V. Granados-Soto,et al.  5‐HT2B Receptor Antagonists Reduce Nerve Injury‐Induced Tactile Allodynia and Expression of 5‐HT2B Receptors , 2015, Drug development research.

[66]  Zhi Xiao,et al.  Antihyperalgesic effect of 5-HT7 receptor activation on the midbrain periaqueductal gray in a rat model of neuropathic pain , 2014, Pharmacology Biochemistry and Behavior.

[67]  A. Dickenson,et al.  Synergistic Effect of 5-Hydroxytryptamine 3 and Neurokinin 1 Receptor Antagonism in Rodent Models of Somatic and Visceral Pain , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[68]  L. Bulathsinhala,et al.  Prevalence, health care utilization, and costs of fibromyalgia, irritable bowel, and chronic fatigue syndromes in the military health system, 2006-2010. , 2014, Military medicine.

[69]  B. Cagnie,et al.  Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. , 2014, Seminars in arthritis and rheumatism.

[70]  H. Bae,et al.  Different role of spinal 5-HT(hydroxytryptamine)7 receptors and descending serotonergic modulation in inflammatory pain induced in formalin and carrageenan rat models. , 2014, British journal of anaesthesia.

[71]  F. Porreca,et al.  Descending pain modulation and chronification of pain , 2014, Current opinion in supportive and palliative care.

[72]  S. Fukudo,et al.  Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[73]  P. Henningsen,et al.  Irritable bowel syndrome: relations with functional, mental, and somatoform disorders. , 2014, World journal of gastroenterology.

[74]  V. Granados-Soto,et al.  Spinal 5-HT5A receptors mediate 5-HT-induced antinociception in several pain models in rats , 2014, Pharmacology Biochemistry and Behavior.

[75]  R. von Känel,et al.  Hypersensitivity and hyperalgesia in somatoform pain disorders. , 2014, General hospital psychiatry.

[76]  Y. Ha,et al.  Role of the 5-HT7 receptor in the effects of intrathecal nefopam in neuropathic pain in rats , 2014, Neuroscience Letters.

[77]  B. Tas,et al.  The TRPM8 channel forms a complex with the 5-HT1B receptor and phospholipase D that amplifies its reversal of pain hypersensitivity , 2014, Neuropharmacology.

[78]  R. Shaker,et al.  Visceral analgesic effect of 5-HT4 receptor agonist in rats involves the rostroventral medulla (RVM) , 2014, Neuropharmacology.

[79]  Andrew W Bundeff,et al.  Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome , 2014, The Annals of pharmacotherapy.

[80]  P. Wiffen,et al.  Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. , 2014, The Cochrane database of systematic reviews.

[81]  W. Guo,et al.  Spinal 5-HT3 receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glial signaling cascade , 2014, Molecular pain.

[82]  M. Franzen,et al.  An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder , 2014, International journal of psychiatry in clinical practice.

[83]  N. Coimbra,et al.  The role of dorsomedial and ventrolateral columns of the periaqueductal gray matter and in situ 5‐HT2A and 5‐HT2C serotonergic receptors in post‐ictal antinociception , 2014, Synapse.

[84]  V. Granados-Soto,et al.  Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats , 2013, Neuroscience.

[85]  A. Eschalier,et al.  Disruption of 5-HT2A Receptor-PDZ Protein Interactions Alleviates Mechanical Hypersensitivity in Carrageenan-Induced Inflammation in Rats , 2013, PloS one.

[86]  A. Meneses,et al.  Role of 5-HT5A receptors in the consolidation of memory , 2013, Behavioural Brain Research.

[87]  M. Zimmermann,et al.  Transient, 5-HT2B receptor–mediated facilitation in neuropathic pain: Up-regulation of PKCγ and engagement of the NMDA receptor in dorsal horn neurons , 2013, PAIN®.

[88]  L. Queiroz Worldwide Epidemiology of Fibromyalgia , 2013, Current Pain and Headache Reports.

[89]  I. Choi,et al.  5-Hydroxytryptamine 1A receptors inhibit glutamate release in rat medullary dorsal horn neurons , 2013, Neuroreport.

[90]  V. Neugebauer,et al.  5-HT2CR blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain , 2013, Molecular pain.

[91]  Rémi Bos,et al.  Activation of 5-HT2A receptors upregulates the function of the neuronal K-Cl cotransporter KCC2 , 2012, Proceedings of the National Academy of Sciences.

[92]  Alexander C. Ford Acupuncture for irritable bowel syndrome. , 2012, Gastroenterology.

[93]  M. Hamon,et al.  GABA, but not opioids, mediates the anti-hyperalgesic effects of 5-HT7 receptor activation in rats suffering from neuropathic pain , 2012, Neuropharmacology.

[94]  V. Granados-Soto,et al.  Secondary mechanical allodynia and hyperalgesia depend on descending facilitation mediated by spinal 5-HT4, 5-HT6 and 5-HT7 receptors , 2012, Neuroscience.

[95]  M. Zimmermann,et al.  Time-Dependent Cross Talk between Spinal Serotonin 5-HT2A Receptor and mGluR1 Subserves Spinal Hyperexcitability and Neuropathic Pain after Nerve Injury , 2012, The Journal of Neuroscience.

[96]  F. Wolfe,et al.  The Role of Antidepressants in the Management of Fibromyalgia Syndrome , 2012, CNS Drugs.

[97]  C. Jatzke,et al.  Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression , 2012, Behavioural pharmacology.

[98]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[99]  H. Diener,et al.  Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study , 2012, The Lancet Neurology.

[100]  J. Galligan,et al.  Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. , 2012, Gastroenterology.

[101]  V. Tayal,et al.  Efficacy of Antidepressants as Analgesics: A Review , 2012, Journal of clinical pharmacology.

[102]  C. Sohn,et al.  Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[103]  H. Kim,et al.  Formulation optimization of solid dispersion of mosapride hydrochloride , 2011, Archives of pharmacal research.

[104]  V. Granados-Soto,et al.  Blockade of 5-HT7 receptors reduces tactile allodynia in the rat , 2011, Pharmacology Biochemistry and Behavior.

[105]  J. Clark,et al.  5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. , 2011, Anesthesiology.

[106]  Pascale Vergne-Sallel,et al.  A randomised, double‐blind, placebo‐controlled trial of dolasetron, a 5‐hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia , 2011, European journal of pain.

[107]  G. Haegeman,et al.  Role of the 5-HT7 Receptor in the Central Nervous System: from Current Status to Future Perspectives , 2011, Molecular Neurobiology.

[108]  E. Lacivita,et al.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. , 2011, Pharmacology & therapeutics.

[109]  L. Arendt-Nielsen,et al.  Endogenous descending modulation: spatiotemporal effect of dynamic imbalance between descending facilitation and inhibition of nociception , 2010, The Journal of physiology.

[110]  J. Schoenen,et al.  EFNS guideline on the treatment of tension‐type headache – Report of an EFNS task force , 2010, European journal of neurology.

[111]  A. Eschalier,et al.  Disrupting 5-HT2A Receptor/PDZ Protein Interactions Reduces Hyperalgesia and Enhances SSRI Efficacy in Neuropathic Pain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  M. Zimmermann,et al.  Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury , 2010, Neuroscience.

[113]  J. Rosmalen,et al.  Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders , 2010, Biological Psychology.

[114]  L. Romero,et al.  Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity , 2010, PAIN.

[115]  T. Dinan,et al.  5‐HT2B receptors modulate visceral hypersensitivity in a stress‐sensitive animal model of brain‐gut axis dysfunction , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[116]  A. Dickenson,et al.  Preclinical and early clinical investigations related to monoaminergic pain modulation , 2009, Neurotherapeutics.

[117]  V. Granados-Soto,et al.  Role of peripheral and spinal 5-HT6 receptors according to the rat formalin test , 2009, Neuroscience.

[118]  M. Murad,et al.  Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. , 2009, JAMA.

[119]  David A. Williams,et al.  Understanding fibromyalgia: lessons from the broader pain research community. , 2009, The journal of pain : official journal of the American Pain Society.

[120]  K. Tominaga,et al.  Efficacy of the 5-HT1A Agonist Tandospirone Citrate in Improving Symptoms of Patients With Functional Dyspepsia: A Randomized Controlled Trial , 2009, The American Journal of Gastroenterology.

[121]  F. Porreca,et al.  Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors , 2009, Brain Research.

[122]  J. V. Steenwinckel,et al.  The 5-HT2A receptor is mainly expressed in nociceptive sensory neurons in rat lumbar dorsal root ganglia , 2009, Neuroscience.

[123]  B. P. Brennan,et al.  Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study , 2009, Human psychopharmacology.

[124]  N. Coimbra,et al.  5-HT1A/1B, 5-HT6, and 5-HT7 serotonergic receptors recruitment in tonic-clonic seizure-induced antinociception: Role of dorsal raphe nucleus , 2009, Experimental Neurology.

[125]  Roja Rahimi,et al.  Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. , 2009, World journal of gastroenterology.

[126]  L. Weaver,et al.  Blockade of the 5‐HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury , 2009, Journal of neuroscience research.

[127]  A. Dolphin,et al.  Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain , 2009, Molecular pain.

[128]  C. Qu,et al.  GABAergic modulation is involved in the ventrolateral orbital cortex 5-HT1A receptor activation-induced antinociception in the rat , 2008, PAIN.

[129]  N. Coimbra,et al.  Serotonergic neurotransmission in the dorsal raphe nucleus recruits in situ 5-HT2A/2C receptors to modulate the post-ictal antinociception , 2008, Experimental Neurology.

[130]  Louis P. Vera-Portocarrero,et al.  Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. , 2008, Gastroenterology.

[131]  M. Kawamura,et al.  The Antiallodynic Effect of Neurotropin® Is Mediated via Activation of Descending Pain Inhibitory Systems in Rats with Spinal Nerve Ligation , 2008, Anesthesia and analgesia.

[132]  W. Bauer,et al.  Involvement of serotonin 2A receptors in the analgesic effect of tramadol in mono-arthritic rats , 2008, Brain Research.

[133]  B. Löwe,et al.  Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. , 2008, General hospital psychiatry.

[134]  J. Hoving,et al.  Antidepressants for non-specific low back pain. , 2008, The Cochrane database of systematic reviews.

[135]  M. Connor,et al.  Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey , 2008, Molecular pain.

[136]  Lei Dong,et al.  Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. , 2007, Chinese medical journal.

[137]  D. Bouhassira,et al.  Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation 1 , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[138]  M. Sasamata,et al.  Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. , 2007, European journal of pharmacology.

[139]  D. Julius,et al.  Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A−/−, 5-HT1B−/−, 5-HT2A−/−, 5-HT3A−/− and 5-HTT−/− knock-out male mice , 2007, PAIN.

[140]  M. Seidel,et al.  5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome , 2007, Rheumatology International.

[141]  H. Obata,et al.  Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in the rats with peripheral nerve injury. , 2007, European journal of pharmacology.

[142]  J. Rietdorf,et al.  Characterization of the Novel Human Serotonin Receptor Subunits 5-HT3C,5-HT3D, and 5-HT3E , 2007, Molecular Pharmacology.

[143]  Jisheng Han,et al.  Roles of 5-Hydroxytryptamine (5-HT) Receptor Subtypes in the Inhibitory Effects of 5-HT on C-Fiber Responses of Spinal Wide Dynamic Range Neurons in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[144]  Robert W Gereau,et al.  Mice Lacking Central Serotonergic Neurons Show Enhanced Inflammatory Pain and an Impaired Analgesic Response to Antidepressant Drugs , 2007, The Journal of Neuroscience.

[145]  Peter Henningsen,et al.  Management of functional somatic syndromes , 2007, The Lancet.

[146]  A. Dogrul,et al.  Systemic morphine produce antinociception mediated by spinal 5‐HT7, but not 5‐HT1A and 5‐HT2 receptors in the spinal cord , 2006, British journal of pharmacology.

[147]  M. Tanabe,et al.  Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors , 2006, Neuropharmacology.

[148]  H. Obata,et al.  Peripheral 5-HT2A receptor antagonism attenuates primary thermal hyperalgesia and secondary mechanical allodynia after thermal injury in rats , 2006, PAIN.

[149]  A. Dickenson,et al.  Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain , 2006, Neuroscience Letters.

[150]  J. Tack,et al.  A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome , 2005, Gut.

[151]  D. Vergé,et al.  Pre‐ and postsynaptic localization of the 5‐HT7 receptor in rat dorsal spinal cord: Immunocytochemical evidence , 2005, The Journal of comparative neurology.

[152]  T. Jensen,et al.  Antidepressants in the treatment of neuropathic pain. , 2005, Basic & clinical pharmacology & toxicology.

[153]  H. Toda,et al.  Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. , 2005, Bioorganic & medicinal chemistry letters.

[154]  Rie Suzuki,et al.  Bad news from the brain: descending 5-HT pathways that control spinal pain processing. , 2004, Trends in pharmacological sciences.

[155]  M. Christie,et al.  Effects of sumatriptan on rat medullary dorsal horn neurons , 2004, Pain.

[156]  D. Vergé,et al.  5‐HT5A receptor localization in the rat spinal cord suggests a role in nociception and control of pelvic floor musculature , 2004, The Journal of comparative neurology.

[157]  D. Siniscalco,et al.  Metabotropic glutamate receptor 5 and dorsal raphe serotonin release in inflammatory pain in rat. , 2004, European journal of pharmacology.

[158]  A. Dickenson,et al.  Descending serotonergic facilitation mediated through rat spinal 5HT3 receptors is unaltered following carrageenan inflammation , 2004, Neuroscience Letters.

[159]  M. Nakashima,et al.  Decrease in serotonin concentration in raphe magnus nucleus and attenuation of morphine analgesia in two mice models of neuropathic pain. , 2004, European journal of pharmacology.

[160]  F. Colpaert,et al.  Continuous Administration of the 5-Hydroxytryptamine1A Agonist (3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl) -amino]-methyl}piperidin-1-yl]-methadone (F 13640) Attenuates Allodynia-Like Behavior in a Rat Model of Trigeminal Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.

[161]  D. Richter,et al.  5-HT4(a) Receptors Avert Opioid-Induced Breathing Depression Without Loss of Analgesia , 2003, Science.

[162]  S. Wessely,et al.  Medically Unexplained Symptoms: Exacerbating Factors in the Doctor-Patient Encounter , 2003, Journal of the Royal Society of Medicine.

[163]  F. Colpaert,et al.  Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640. , 2003, European journal of pharmacology.

[164]  Winfried Rief,et al.  A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. , 2003, Journal of psychosomatic research.

[165]  K. Lawson Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? , 2002, Expert opinion on investigational drugs.

[166]  K. Hackshaw,et al.  Reduced basal release of serotonin from the ventrobasal thalamus of the rat in a model of neuropathic pain , 2002, PAIN.

[167]  P. Schoenfeld,et al.  The epidemiology of irritable bowel syndrome in North America: a systematic review , 2002, American Journal of Gastroenterology.

[168]  M. Millan Descending control of pain , 2002, Progress in Neurobiology.

[169]  P. Keck,et al.  A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. , 2002, The American journal of medicine.

[170]  A. Basbaum,et al.  The 5-HT3 Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors , 2002, The Journal of Neuroscience.

[171]  K. Hole,et al.  Activation of spinal serotonin2A/2C receptors augments nociceptive responses in the rat , 2001, Brain Research.

[172]  R Hen,et al.  Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. , 2001, European journal of pharmacology.

[173]  H. Wolf Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists , 2000, Scandinavian journal of rheumatology. Supplement.

[174]  T. Patterson,et al.  Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity , 1999, PAIN.

[175]  S. Wessely,et al.  Functional somatic syndromes: one or many? , 1999, The Lancet.

[176]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[177]  John A. Peters,et al.  The 5-HT3B subunit is a major determinant of serotonin-receptor function , 1999, Nature.

[178]  P. Szot,et al.  Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing , 1998, Neuropharmacology.

[179]  M. Zhuo,et al.  Biphasic modulation of spinal nociceptive transmission from the medullary raphe nuclei in the rat. , 1997, Journal of neurophysiology.

[180]  C. Schmid,et al.  A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. , 1996, Arthritis and rheumatism.

[181]  J. Olesen,et al.  A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[182]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[183]  R. K. Price,et al.  Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. , 1993, Archives of internal medicine.

[184]  D. Hoyer,et al.  A proposed new nomenclature for 5-HT receptors. , 1993, Trends in pharmacological sciences.

[185]  J. Schwartz,et al.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. , 1993, Biochemical and biophysical research communications.

[186]  M. Erlander,et al.  Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[187]  M. Mattei,et al.  Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. , 1993, Molecular pharmacology.

[188]  J. Levine,et al.  A possible indicator of functional pain: poor pain scale correlation , 1991, Pain.

[189]  J. Hsieh,et al.  Neuroimaging Studies of Primary Dysmenorrhea. , 2018, Advances in experimental medicine and biology.

[190]  U. Ladabaum,et al.  Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[191]  Antidepressants: suicidality risk is `strongly' age-related , 2009 .

[192]  O. Plesh,et al.  Temporomandibular joint and muscle disorder-type pain in U.S. adults: the National Health Interview Survey. , 2008, Journal of orofacial pain.

[193]  T. Gan Selective Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting , 2005, CNS drugs.

[194]  I. Russell,et al.  Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. , 1992, The Journal of rheumatology.